PubMed
Open access
Society journal
Impact Factor 3.7

European Association of Nuclear Medicine

EANM on MedicMess

EJNMMI Radiopharmacy and Chemistry

In PubMed through PubMed Central. Fully open access. Published by Springer for the European Association of Nuclear Medicine.

EJNMMI Radiopharmacy and Chemistry publishes research on imaging agents and radionuclide-based therapies for nuclear medicine and molecular imaging. Its scope includes radionuclide production, radiochemistry, radiopharmaceuticals, biological evaluation, and the safety and regulation of these agents.
Reviewed byDr Robert BaxterDr Robert Baxter· Junior Clinical Fellow, Acute Medical Unit· Updated 14 Oct 2026

Publishing in EJNMMI Radiopharmacy and Chemistry

EJNMMI Radiopharmacy and Chemistry publishes open access work on agents for nuclear medicine and molecular imaging. It serves chemists, pharmacists, biologists and other scientists developing radionuclides, radiopharmaceuticals and imaging probes. The journal also covers practical methods, harmonisation, safety and regulatory issues in the field. It belongs to the EJNMMI journal family.

The guide lists Research Articles, Debates, Guideline Articles, Letters to the Editor, Methodology Articles, Reviews, Position Papers and Short Communications. Letters may include brief case or research reports, and reviews may include systematic syntheses. Every accepted article carries a £1,590 publication charge before applicable taxes; funding, discounts and waivers may be available. The journal uses single anonymous peer review and reports a median of seven days from submission to first decision. Research letters receive peer review, while other letters may be reviewed at the editors' discretion.

Free subscriber access

Free with a subscription: the author guide in one place

Word limits, abstract lengths and fees for each article type, and a checklist before you submit. Enter your email to unlock this journal and every other guide.

  • Research Articles

    Original research on radiopharmaceuticals, radionuclides or molecular imaging agents.

    Words
    —
    Abstract
    350
    Figures & tables
    —
    References
    —
    Structured abstract
  • Debates

    Arguments on scientific, social or ethical questions within the journal's scope.

    Words
    —
    Abstract
    350
    Figures & tables
    —
    References
    —
    Structured abstract
  • Guideline Articles

    Evidence based guidance on practice, management or policy.

    Words
    —
    Abstract
    350
    Figures & tables
    —
    References
    —
    Structured abstract
  • Letters to the Editor

    Reanalysis, commentary or brief case and research reports; research reports receive peer review.

    Words
    500
    Abstract
    —
    Figures & tables
    —
    References
    —
  • Methodology Articles

    A tested new or improved experimental or computational method.

    Words
    —
    Abstract
    350
    Figures & tables
    —
    References
    —
    Structured abstract
  • Reviews

    Systematic syntheses, progress reviews and critical assessments within the journal's scope.

    Words
    —
    Abstract
    350
    Figures & tables
    —
    References
    —
    Structured abstract
  • Position Papers

    A reasoned position on a topic in radiopharmacy or molecular imaging.

    Words
    —
    Abstract
    350
    Figures & tables
    —
    References
    —
    Structured abstract
  • Short Communications

    Extensions, confirmatory findings or negative results building on earlier research.

    Words
    —
    Abstract
    350
    Figures & tables
    —
    References
    —

Every accepted article incurs a £1,590 APC, or US$2,290 or €1,990, plus applicable taxes. The price is set at acceptance. Institutional agreements may cover costs; eligible low-income country authors may receive discounts or waivers, and other authors may request relief for financial need at submission.

Before you submit

  • Explain the journal fit, policy issues, competing interests and all authors' approval in the cover letter.
  • Provide a data availability statement and each required declaration heading, even when it is not applicable.
  • Follow the radiochemistry nomenclature guidance endorsed by the EJNMMI journal family.
  • Document any large language model use in the Methods or another suitable section.
  • Request a discretionary APC discount or waiver at submission, not during review or after acceptance.

Present it first.

Similar journals.

Frequently asked

Is EJNMMI Radiopharmacy and Chemistry indexed in PubMed?
Yes, through PubMed Central. Its articles are deposited in PMC and appear in PubMed with a PMID; it is not indexed in MEDLINE.
How much does it cost to publish in EJNMMI Radiopharmacy and Chemistry?
The article processing charge is £1,590.
Does EJNMMI Radiopharmacy and Chemistry accept case reports?
Yes. EJNMMI Radiopharmacy and Chemistry publishes case reports.
What is the Impact Factor of EJNMMI Radiopharmacy and Chemistry?
EJNMMI Radiopharmacy and Chemistry states an Impact Factor of 3.7 for 2025.
How long does EJNMMI Radiopharmacy and Chemistry take to decide?
About 7 days from submission to first decision.
What kind of peer review does EJNMMI Radiopharmacy and Chemistry use?
Single-blind peer review.

PubMed via PMC · APC £1,590 · First decision in 7 days

Accepted work
Original research · Case report · Systematic review · Literature review
Acceptance rate
Not stated
Peer review
Single-blind
Access
Free to read
Author guide

Checked against the journal’s author guide · updated 14 Oct 2026